Answers are grounded in this paper and cite their sources.
C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (pIC-MPGN) are rare, progressive kidney disorders. Here, we aim to assess real-world treatment patterns and patient burden. Data were from Adelphi Real World C3G and IC-MPGN Disease Specific Programmes (DSPs)™, cross-sectional surveys in Europe and US, conducted 2022–2024. Physicians reported on clinical and treatment data. Patients completed the Work Productivity and Activity Impairment (WPAI) and EQ-5D measures. 72 physicians reported data on 236 patients with C3G and 190 with pIC-MPGN, with 36 and 47 patients completing surveys, respectively. Mean (standard deviation) age was 42.9 (17.6) in C3G and 41.8 (18.2) in pIC-MPGN; the majority of patients were male and White. Mean time between initial consultation and diagnosis was 12.7 (37.3) weeks (C3G) and 8.3 (14.7) weeks (pIC-MPGN), and most common reasons for diagnostic delay were waiting to conduct biopsies (C3G, 41.0%) or tests (pIC-MPGN, 42.9%). Mean proteinuria at survey was 2.3 (2.6) g/24 h (C3G) and 1.6 (1.4) g/24 h (pIC-MPGN), with mean estimated glomerular filtration rates of 50.0 (25.9) (C3G) and 52.4 (25.2) ml/min/1·73 m 2 (pIC-MPGN). Patients most commonly received angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (C3G: 70.5%, pIC-MPGN: 73.1%). Mean WPAI activity impairment was 37.9% (22.9) (C3G) and 36.0% (22.9) (pIC-MPGN). Mean EQ-5D utility values were 0.80 (0.28) (C3G) and 0.83 (0.11) (pIC-MPGN), while mean VAS scores were 66.9 (17.9) and 69.0 (12.6), respectively. Patients continue to experience diagnostic delay, kidney damage and impaired quality of life, highlighting the need for use of newer, targeted treatment. Not applicable.
No takes yet. Share an insight, caveat, or question.
Norouzi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: